Business Wire

Amazfit Introduces the Future of Sports Technology at CES 2026

6.1.2026 16:00:00 EET | Business Wire | Press release

Share

Amazfit, a leading global smart wearable brand by Zepp Health (NYSE: ZEPP), returns to CES 2026 with a bold vision for the future of sports technology. Long known for accessible, performance-driven wearables, the brand is entering a new era defined by thoughtful design, innovation, and an unmistakable athletic spirit.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106362840/en/

At CES 2026, Amazfit will spotlight how its connected ecosystem supports the full spectrum of an active lifestyle powered by real-world use cases and trusted by elite athletes, including Derrick Henry, Gabby Thomas, Hunter McIntyre, and Grant Fisher.

At CES 2026, Amazfit will spotlight how its connected ecosystem supports the full spectrum of an active lifestyle powered by real-world use cases and trusted by elite athletes, including Derrick Henry, Gabby Thomas, Hunter McIntyre, and Grant Fisher. Amazfit’s philosophy reflects a commitment to technology that fits seamlessly into everyday routines.

This vision comes to life through new concepts and launches, including:

V1TAL Food Camera: A Concept Expanding the Amazfit Performance Ecosystem

Athletes don’t just eat—they fuel with intention. At CES 2026, Amazfit will preview the V1TAL Food Camera, an early-stage concept exploring how nutrition can become a measurable input within a connected performance ecosystem. Designed to analyze real-world eating behavior, V1TAL captures not only what you consume, but how, when, and in what context you fuel.

As a proof point of Amazfit’s ecosystem-first approach, the concept shows how nutrition data can integrate alongside training load, recovery, and health metrics already tracked by Amazfit wearables, with all insights flowing directly into the Zepp App. Building on the Zepp App’s Food Log feature—introduced last year and enabling photo-based meal uploads—the V1TAL Food Camera concept is envisioned as an advanced companion that further analyzes nutrition inputs, turning everyday meals into actionable intelligence across the broader Amazfit performance ecosystem.

The V1TAL Food Camera shown at CES is a concept only, not a product launch. The units on display are prototypes, and features, design, pricing, and timing remain under development.

Amazfit Helio Glasses: A Concept Built to Keep Runners Focused

At CES 2026, Amazfit will preview Helio Glasses, an early-stage concept exploring how performance data can move beyond the wrist to support a safer, more immersive training experience. Purpose-built for runners, the lightweight glasses combine essential eye protection with a minimalist heads-up display—so critical data runs alongside you, without the need to look down.

When paired with an Amazfit smartwatch, Helio Glasses present real-time metrics such as pace, heart rate, and navigation directly within the runner’s forward field of vision during activities like running or cycling. By keeping the head up and focus locked, the concept is designed to address two core pain points of running: safety and concentration.

As a proof point of Amazfit’s ecosystem-first approach, Helio Glasses demonstrate how hardware, software, and data work together across devices, with insights flowing seamlessly through the Zepp App alongside training, recovery, and health data from Amazfit wearables. Built with impact-resistant polycarbonate lenses and designed to be water- and sweat-resistant, the glasses can be controlled via integrated frame buttons or a paired Amazfit watch, with battery life engineered to last the duration of a full marathon.

Currently the Amazfit Helio Glasses are a concept only, not a product launch. The units shown at CES are engineering prototypes, and final design, features, pricing, and timing remain in development, with a potential release targeted for the second half of 2026.

Active Max: Bigger, Brighter & Built for Performance

As the newest member within the Active family, the all-new Active Max blends a bold 1.5" display, powerful 24-day battery life, and advanced training tools that keep you inspired and on track. Active Max features enhancements across three dimensions: a bigger display, bigger storage, and bigger battery life. Pairing lightweight durability with 5 ATM water resistance and 170+ sport modes, Active Max offers versatility for strength sessions, running, and outdoor activities. Available now for $169 on amazfit.com and Amazon.

Visit Amazfit at CES 2026: The Future of Sports Technology Starts Here

Amazfit’s full range of athlete-led innovations will be on display at CES at their Booth #52344 at the Venetian Expo, Level 2. Attendees can experience an immersive walk-through demonstrating the next era of Amazfit as a global sports technology brand.

For more information, please visit www.amazfit.com and follow us on Facebook, Instagram, Twitter, and YouTube. Media and influencers are welcome to sign up to Amazfit Affiliate programs on Amazon and Commission Junction via the link.

Beyond Amazfit smart wearables, Zepp Health continues to expand its broader health ecosystem through Zepp Clarity, offering a lineup of over-the-counter (OTC) hearing aids designed for individuals with mild-to-moderate hearing loss. The Zepp Clarity One, Pixie, and Omni models combine discreet, modern design with customizable sound, intuitive self-fitting, and optional Bluetooth connectivity. At CES 2026, Zepp Clarity will showcase its hearing solutions at Pepcom, while continuing to grow its presence through direct-to-consumer channels and major retail partners including Target, Best Buy, and Amazon, and actively expanding its distribution partner network nationwide.

About Amazfit

Amazfit, a global smart wearable and fitness leader is part of Zepp Health (NYSE: ZEPP), a health technology company with its principal office based in Gorinchem, the Netherlands. Zepp Health operates as a distributed organization, with team members and offices across the Americas, Europe, Asia, and other global markets.

Amazfit builds smart wearables designed around movement—training with intention, recovery with balance, and evolution over time. Built for the way people train today, Amazfit blends endurance, strength, and recovery into a single, coherent rhythm to support sustainable progress over time.

Behind Amazfit is Zepp, which builds the intelligence that supports its training experience. For more information, visit www.amazfit.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260106362840/en/

Contacts

Media Contact
Max Borges Agency for Amazfit
amazfit@maxborgesagency.com

Mary Thompson Woodbury
Head of PR, Amazfit North America
Mary.woodbury@zepp.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye